Early onset of increased transcapillary albumin escape in awake diabetic rats.
Alteration in transcapillary albumin escape rate (TERalb) is an indicator of changes in macromolecular movement at the capillary filtering bed, which can change the balance of Starling forces for fluid movement from the vasculature to the interstitium and has an impact on volume homeostasis. TERalb can be affected by morphological changes in the capillary membrane and/or alterations in the Starling forces driving larger solutes across the capillary membrane via convection. Previous studies have demonstrated an increased TERalb in established insulin-dependent diabetes (IDDM); however, whether increased TERalb is the result of morphological alterations in the microvasculature or contributes to microangiopathies could not be resolved. TERalb was examined in awake Wistar rats with untreated IDDM induced by streptozocin infusion (65 mg/kg body wt i.v.) at 24 h and 7 and 15 days and compared with control and insulin-treated 7-day IDDM rats. Increased TERalb occurred at the 24-h time point and remained elevated at 7 and 15 days of IDDM (P less than 0.05). Blood volume remained unchanged; however, systemic protein concentration increased from 4.9 +/- 0.1 g/dl in controls to 6.4 +/- 0.4 g/dl in 15-day IDDM rats. Blood glucose was significantly increased, and glycosuria was evident at all three time points of IDDM. The observed increase in TERalb within 24 h of IDDM is indicative of a functional change in the Starling forces in the capillaries, because specific morphological capillary damage is not evident at this time point in the model. The early onset of TERalb in IDDM could indicate functional changes, such as capillary hypertension, and may contribute to future vascular complications in established IDDM.
Tucker
B J
BJ
Department of Medicine, University of California, School of Medicine, San Diego, La Jolla.
D000818:Animals; D001485:Basement Membrane / Q000648:ultrastructure; D001786:Blood Glucose / Q000032:analysis; D002196:Capillaries / Q000473:pathology / Q000502:physiology / Q000648:ultrastructure; D002199:Capillary Permeability / Q000502:physiology*; D002404:Catheterization; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D051381:Rats; D011919:Rats, Inbred Strains; D012709:Serum Albumin / Q000493:pharmacokinetics*; D013311:Streptozocin / Q000008:administration & dosage; D014851:Wakefulness / Q000502:physiology*
D001786:Blood Glucose; D012709:Serum Albumin; D013311:Streptozocin